Genmab — December 2018
-
in addition to that; it is a pilot program; i believe they will try this out with the Big Pharma, that have a lot of staff and experience with sBLA etc; so JNJ will be one of only a few that have a chance in my opinion, and Dara is their fastest growing drug, AND FDA has already goodplenty of experience with & and knowledge off Dara
-
-
-
Et hus som jeg ikke kender så meget til - Zack - har løftet fra "strong sell" til "hold". Jf. pressoracle.com. Som jeg ikke kendte i forvejen.
-
Zack er vist bare en maskinopsamler af analyser.
-
Medicinalfirmaer skrotter midler i stor stil: Omkostninger er blevet for store
Verdens største medicinalselskaber lukker programmer ned i deres forskningsafdelinger som sjældent set før, for omkostningerne har vokset sig så store, at selskaberne skal satse smalt og ikke bredt. Og det er en trend, som også Novo Nordisk er med på.
(medwatch.dk)
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind